secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001232524-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B
--------------------------------------------------------------------------

- Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.
- GAAP diluted EPS $8.65 (FY2024) vs $6.10 (FY2023); Non-GAAP diluted EPS $20.90 vs $18.29.
- Xywav+Epidiolex grew 16% and 15% YoY; oncology revenue surpassed $1.1B (+9%).
- 2025 guidance: total revenue $4.15-4.40B; GAAP EPS $9.15-11.50; Non-GAAP EPS $22.50-24.00.
- Cash from ops $1.4B; voluntary $750M debt prepayment in Jan 2025; Ziihera launch initial sales $1.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/0001232524-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/jazz-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001232524-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer